NO20060324L - [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni - Google Patents

[1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni

Info

Publication number: NO20060324L
Authority: NO; Norway
Prior art keywords: treatment; naphthyridin; schizophrenia; ones; related compounds
Prior art date: 2003-08-22

Application number

NO20060324A

Other languages

English (en)

Norwegian (no)

Inventor

Joseph Thomas Repine

Jerry Clark

Jamie Davis

David Favor

Lorraine Fay

Lloyd Franklin

Kevin Henegar

Douglas Johnson

Brian Nichelson

Ligong Ou

Michael Walters

Andrew David Withe

Zhijian Zhu

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-22

Filing date

2006-01-20

Publication date

2006-05-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34216117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060324(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-01-20 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2006-05-18 Publication of NO20060324L publication Critical patent/NO20060324L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Psychology (AREA)
Obesity (AREA)
Anesthesiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20060324A 2003-08-22 2006-01-20 [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni NO20060324L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49737003P	2003-08-22	2003-08-22
PCT/IB2004/002665 WO2005019215A1 (en)	2003-08-22	2004-08-13	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Publications (1)

Publication Number	Publication Date
NO20060324L true NO20060324L (no)	2006-05-18

Family

ID=34216117

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20060324A NO20060324L (no)	2003-08-22	2006-01-20	[1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni

Country Status (35)

Country	Link
US (3)	US7160888B2 (es)
EP (1)	EP1660497A1 (es)
JP (1)	JP4034811B2 (es)
KR (2)	KR100801794B1 (es)
CN (1)	CN100422181C (es)
AP (1)	AP2006003525A0 (es)
AR (1)	AR045386A1 (es)
AU (1)	AU2004266191B2 (es)
BR (1)	BRPI0413860A (es)
CA (1)	CA2538915C (es)
CR (2)	CR8254A (es)
CU (1)	CU23464B7 (es)
EA (1)	EA009645B1 (es)
EC (1)	ECSP066391A (es)
GE (1)	GEP20084447B (es)
GT (1)	GT200500007A (es)
HN (1)	HN2004000319A (es)
IL (1)	IL173439A0 (es)
IS (1)	IS8267A (es)
MA (1)	MA28003A1 (es)
ME (1)	MEP45308A (es)
MX (1)	MXPA06002070A (es)
MY (1)	MY140693A (es)
NL (1)	NL1026892C2 (es)
NO (1)	NO20060324L (es)
NZ (1)	NZ545078A (es)
OA (1)	OA13238A (es)
PA (1)	PA8609701A1 (es)
PE (1)	PE20051039A1 (es)
RS (1)	RS20060129A (es)
TN (1)	TNSN06063A1 (es)
TW (1)	TWI298327B (es)
UA (1)	UA82541C2 (es)
WO (1)	WO2005019215A1 (es)
ZA (1)	ZA200601526B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9904723D0 (sv)	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission II
USRE46117E1 (en)	1999-12-22	2016-08-23	Teva Pharmaceuticals International Gmbh	Modulators of dopamine neurotransmission
SE9904724D0 (sv)	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission I
EP1408976B3 (en) *	2001-07-20	2010-08-25	Psychogenics Inc.	Treatment for attention-deficit hyperactivity disorder
US7160888B2 (en) *	2003-08-22	2007-01-09	Warner Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7851629B2 (en)	2004-06-08	2010-12-14	Nsab, Filial Af Neurosearch Sweden Ab, Sverige	Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
EP1773772B1 (en) *	2004-06-08	2010-06-02	NSAB, Filial af NeuroSearch Sweden AB, Sverige	New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
DE602005017784D1 (de)	2004-06-08	2009-12-31	Nsab, Filial Af Neurosearch Sweden Ab	Neue disubstituierte phenylpiperidine als modulatoren der dopamin- und serotoninneurotransmission
MX2007004215A (es)	2004-10-13	2007-12-12	Neurosearch Sweden Ab	Proceso para la sintesis de 4-(3-metansulfonilfenil)-1-n- propilpiperidina.
FR2877005A1 (fr) *	2004-10-22	2006-04-28	Bioprojet Soc Civ Ile	Nouveaux derives d'arylpiperazine
EP1846411A4 (en)	2005-01-25	2010-08-04	Glaxo Group Ltd	ANTIBACTERIAL ACTIVE SUBSTANCES
WO2006090273A2 (en) *	2005-02-22	2006-08-31	Warner-Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006090272A1 (en) *	2005-02-22	2006-08-31	Warner-Lambert Company Llc	Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
EA200701856A1 (ru) *	2005-04-01	2008-02-28	Уорнер-Ламберт Компани Ллс	Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
EP1869019B1 (en) *	2005-04-08	2014-08-27	Pfizer Products Inc.	Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
TWI320783B (en)	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
JP4315393B2 (ja) *	2005-04-14	2009-08-19	大塚製薬株式会社	複素環化合物
RU2402549C3 (ru) *	2005-04-14	2022-03-10	Оцука Фармасьютикал Ко., Лтд.	Пиперазин-замещенные бензотиофены для лечения психических расстройств
TWI329641B (en) *	2005-08-31	2010-09-01	Otsuka Pharma Co Ltd	(benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
CA2624965A1 (en)	2005-10-07	2007-04-19	Exelixis, Inc.	Pyridopyrimidinone inhibitors of pi3k.alpha.
SE529246C2 (sv)	2005-10-13	2007-06-12	Neurosearch Sweden Ab	Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
EP1945638A2 (en) *	2005-10-31	2008-07-23	Pfizer Products Inc.	Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-but oxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one
EP1988077A4 (en) *	2006-02-23	2009-09-02	Shionogi & Co	NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
WO2007116265A1 (en) *	2006-03-31	2007-10-18	Pfizer Products Inc.	Process for making a tetrahydro-pyridoazepin-8-one compound
WO2007136790A2 (en)	2006-05-18	2007-11-29	Mannkind Corporation	Intracellular kinase inhibitors
ES2366489T3 (es)	2006-09-15	2011-10-20	Pfizer Products Inc.	Compuesto de pirido (2,3-d) piridinona y sus uso como inhibidores de pi3.
US20100093738A1 (en) *	2006-10-06	2010-04-15	Basf Se	Fungicidal Compounds and Fungicidal Compositions
JP4540700B2 (ja) *	2006-10-13	2010-09-08	大塚製薬株式会社	医薬
AR063302A1 (es) *	2006-10-13	2009-01-21	Otsuka Pharma Co Ltd	Derivados de 4-benzo[b]tiofen-4-il-piperazin-1-il con accion antagonista del receptor 5-ht2a de serotonina y receptor de adrenalina alfa1 y agonista parcial del receptor d2, una composicion farmaceutica que lo comprende y un proceso para producirla.
WO2008084324A1 (en) *	2007-01-04	2008-07-17	Pfizer Products Inc.	Naphthyridinone compound
JP4785881B2 (ja) *	2007-02-27	2011-10-05	大塚製薬株式会社	医薬
CL2008001002A1 (es)	2007-04-11	2008-10-17	Actelion Pharmaceuticals Ltd	Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
NZ582124A (en) *	2007-05-21	2012-07-27	Reviva Pharmaceuticals Inc	Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
TW200904446A (en) *	2007-05-30	2009-02-01	Wyeth Corp	Antidepressant heteroaryl derivatives of heterocycle-fused benzodioxans
US7928111B2 (en) *	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
JP5323088B2 (ja)	2007-12-18	2013-10-23	アクテリオンファーマシューティカルズリミテッド	５−アミノシクリルメチル−オキサゾリジン−２−オン誘導体
EP2322520A4 (en)	2008-07-28	2012-04-25	Jiangsu Guohua Invest Co Ltd	ARALKYL SUBSTITUTED PIPERIDINE OR PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SCHIZOPHRENIA
WO2010014666A2 (en)	2008-07-31	2010-02-04	Senomyx, Inc.	Processes and intermediates for making sweet taste enhancers
MX2011005905A (es)	2008-12-12	2011-06-20	Actelion Pharmaceuticals Ltd	Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano.
MA33053B1 (fr) *	2009-01-23	2012-02-01	Tadeka Pharmaceutical Company Ltd	Inhibiteurs de la poly(adp-ribose) polymerase (parp)
WO2010099503A1 (en) *	2009-02-26	2010-09-02	Reviva Pharmaceuticals, Inc.	Compositions, synthesis, and methods of utilizing quinazolinedione derivatives
JP5732453B2 (ja)	2009-06-25	2015-06-10	アルカーメスファーマアイルランドリミテッド	Ｎｈ酸性化合物のプロドラッグ
US8431576B2 (en)	2009-06-25	2013-04-30	Alkermes Pharma Ireland Limited	Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011140183A1 (en)	2010-05-04	2011-11-10	Alkermes, Inc.	Process for synthesizing oxidized lactam compounds
US8592427B2 (en)	2010-06-24	2013-11-26	Alkermes Pharma Ireland Limited	Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9156822B2 (en)	2010-07-02	2015-10-13	The University Of North Carolina At Chapel Hill	Functionally selective ligands of dopamine D2 receptors
WO2012080284A2 (en)	2010-12-17	2012-06-21	F. Hoffmann-La Roche Ag	Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
LT2685979T (lt)	2011-03-18	2016-12-12	Alkermes Pharma Ireland Limited	Injekcinės farmacinės kompozicijos, apimančios vandenyje netirpų antipsichotiką, sorbitano lauratą ir polisorbatą 20
JO3227B1 (ar)	2011-09-08	2018-03-08	Otsuka Pharma Co Ltd	مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
MX347209B (es)	2011-12-08	2017-04-19	Teva Pharmaceuticals Int Gmbh	La sal de bromhidrato de pridopidina.
AU2012351747B2 (en)	2011-12-15	2016-05-12	Alkermes Pharma Ireland Limited	Prodrugs of secondary amine compounds
CA2867137C (en)	2012-03-19	2020-12-08	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
WO2013142198A1 (en)	2012-03-19	2013-09-26	Alkermes Pharma Ireland Limited	Pharmaaceutical compositions comprising fatty acid esters
ES2764383T3 (es)	2012-03-19	2020-06-03	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que comprenden ésteres de glicerol
CN104470585A (zh)	2012-04-04	2015-03-25	爱华克斯国际有限公司	用于联合疗法的药物组合物
AU2013259551B2 (en) *	2012-05-09	2017-11-02	Sunovion Pharmaceuticals Inc.	Heteroaryl compounds and methods of use thereof
NZ631345A (en)	2012-09-19	2017-06-30	Alkermes Pharma Ireland Ltd	Pharmaceutical compositions having improved storage stability
BR112016021535A8 (pt)	2014-03-20	2021-07-20	Alkermes Pharma Ireland Ltd	kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
CN104785295B (zh) *	2015-03-18	2018-03-06	杭州创培信息科技有限公司	一种高选择性多巴胺铂炭催化剂的制备方法
HK1255074A1 (zh)	2015-07-01	2019-08-02	Crinetics Pharmaceuticals, Inc.	生长抑素调节剂及其用途
ES2879995T3 (es)	2015-12-10	2021-11-23	Ptc Therapeutics Inc	Métodos para el tratamiento de la enfermedad de Huntington
CN106242934A (zh) *	2016-07-26	2016-12-21	云南民族大学	一种酮的β‑位C‑H键乙酰氧化合成方法
EP4151627A1 (en)	2017-06-05	2023-03-22	PTC Therapeutics, Inc.	Compounds for treating huntington's disease
MX2019015578A (es)	2017-06-28	2020-07-28	Ptc Therapeutics Inc	Metodos para tratar la enfermedad de huntington.
CN111163838B (zh)	2017-06-28	2023-03-28	Ptc医疗公司	用于治疗亨廷顿氏病的方法
EP3658560A4 (en)	2017-07-25	2021-01-06	Crinetics Pharmaceuticals, Inc.	SOMATOSTAT IN MODULATORS AND USES THEREOF
CA3092335A1 (en)	2018-03-05	2019-09-12	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy
US20210017174A1 (en)	2018-03-07	2021-01-21	Bayer Aktiengesellschaft	Identification and use of erk5 inhibitor
MX2020009957A (es)	2018-03-27	2021-01-15	Ptc Therapeutics Inc	Compuestos para el tratamiento de enfermedad de hungtinton.
WO2020005882A1 (en)	2018-06-27	2020-01-02	Ptc Therapeutics, Inc.	Heteroaryl compounds for treating huntington's disease
EA202092899A1 (ru)	2018-06-27	2021-05-14	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	Гетероарильные соединения для лечения болезни гентингтона
SG11202012674PA (en)	2018-06-27	2021-01-28	Ptc Therapeutics Inc	Heterocyclic and heteroaryl compounds for treating huntington's disease
JP7453210B2 (ja)	2018-08-07	2024-03-19	フィルメニッヒインコーポレイテッド	５－置換４－アミノ－１Ｈ－ベンゾ［ｃ］［１，２，６］チアジアジン２，２－ジオキシド並びにその配合物及び使用
JP7637049B2 (ja)	2018-08-13	2025-02-27	エフ．ホフマン－ラロシュアーゲー	モノアシルグリセロールリパーゼ阻害剤としての新規の複素環化合物
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en)	2019-02-15	2020-08-20	Incyte Corporation	Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en)	2019-03-05	2022-10-18	Incyte Corporation	Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en)	2019-03-29	2020-10-08	Incyte Corporation	Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en)	2019-05-01	2022-09-20	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en)	2019-05-01	2020-11-05	Incyte Corporation	N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
CR20220066A (es)	2019-08-14	2022-11-28	Incyte Corp	Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CN114269755A (zh)	2019-09-12	2022-04-01	豪夫迈·罗氏有限公司	作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物
JOP20220087A1 (ar)	2019-10-11	2023-01-30	Incyte Corp	أمينات ثنائية الحلقة كمثبطات لـ cdk2
CN114634479B (zh) *	2020-12-16	2025-02-07	北京盈科瑞创新药物研究有限公司	一种派嗪衍生物、其制备方法及应用
WO2022212538A1 (en) *	2021-03-31	2022-10-06	Blueprint Medicines Corporation	Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
US11981671B2 (en)	2021-06-21	2024-05-14	Incyte Corporation	Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors
KR20240161147A (ko)	2022-03-14	2024-11-12	슬랩 파마슈티컬스 엘엘씨	다중 사이클릭 화합물
WO2023186023A1 (zh) *	2022-03-30	2023-10-05	苏州旺山旺水生物医药股份有限公司	一类n-取代的喹啉酮化合物、其制备方法和用途
CN114805081B (zh) *	2022-05-20	2024-09-24	都创(上海)医药开发有限公司	一种基于微通道连续流技术快速制备1-萘胺的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5649361A (en)	1979-09-28	1981-05-02	Otsuka Pharmaceut Co Ltd	Carbostyril derivative
JPH07165720A (ja) *	1988-10-31	1995-06-27	Otsuka Pharmaceut Co Ltd	カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
JP2608788B2 (ja) *	1988-10-31	1997-05-14	大塚製薬株式会社	精神分裂病治療剤
US5006528A (en)	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
US5153206A (en)	1988-12-02	1992-10-06	Pfizer Inc.	Arylpiperidine derivatives
DE69021645T2 (de)	1989-05-19	1996-02-22	Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J.	N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5350747A (en)	1989-07-07	1994-09-27	Pfizer Inc	Heteroaryl piperazine antipsychotic agents
WO1991000863A1 (en) *	1989-07-07	1991-01-24	Pfizer Inc.	Heteroaryl piperazine antipsychotic agents
US5032598A (en)	1989-12-08	1991-07-16	Merck & Co., Inc.	Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
AU645681B2 (en) *	1991-05-02	1994-01-20	John Wyeth & Brother Limited	Piperazine derivatives
IE914218A1 (en)	1991-09-11	1993-03-24	Mcneilab Inc	Novel 4-arylpiperazines and 4-arylpiperidines
US5206366A (en)	1992-08-26	1993-04-27	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds
TW444018B (en)	1992-12-17	2001-07-01	Pfizer	Pyrazolopyrimidines
TW336932B (en)	1992-12-17	1998-07-21	Pfizer	Amino-substituted pyrazoles
EP0674641B1 (en)	1992-12-17	1999-03-03	Pfizer Inc.	Pyrrolopyrimidines as crf antagonists
JP2862374B2 (ja)	1992-12-17	1999-03-03	フアイザー・インコーポレイテツド	Ｃｒｆアンタゴニスト活性を有するピラゾール及びピラゾロピリミジン
WO1994013661A1 (en)	1992-12-17	1994-06-23	Pfizer Inc.	Substituted pyrazoles as crf antagonists
FR2699918B1 (fr)	1992-12-30	1995-03-17	Pf Medicament	Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments.
JPH07247271A (ja) *	1994-01-21	1995-09-26	Otsuka Pharmaceut Co Ltd	３，４−ジヒドロカルボスチリル誘導体
FR2731222A1 (fr)	1995-03-02	1996-09-06	Pf Medicament	Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
JP2900130B2 (ja) *	1995-03-16	1999-06-02	大塚製薬株式会社	カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
JP2987484B2 (ja) *	1995-03-16	1999-12-06	大塚製薬株式会社	カルボスチリル誘導体の製造方法
IL117923A (en)	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
WO1997003067A1 (en)	1995-07-13	1997-01-30	Knoll Aktiengesellschaft	Piperazine derivatives as therapeutic agents
WO1997014419A1 (en)	1995-10-20	1997-04-24	Flora Inc.	Transdermal delivery of alpha adrenoceptor blocking agents
JPH09241161A (ja)	1996-03-08	1997-09-16	Nippon Shinyaku Co Ltd	医薬
US5912256A (en)	1996-06-20	1999-06-15	Eli Lilly And Company	Compounds having effects on serotonin-related systems
US5945422A (en)	1997-02-05	1999-08-31	Warner-Lambert Company	N-oxides of amino containing pyrido 2,3-D! pyrimidines
US6498163B1 (en)	1997-02-05	2002-12-24	Warner-Lambert Company	Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
FR2761071B1 (fr)	1997-03-20	1999-12-03	Synthelabo	Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique
FR2769912B1 (fr)	1997-10-16	2000-03-10	Pf Medicament	Nouveaux derives de la 3-oxo- (2h)-1,2,4 triazine leur preparation et leur application en therapeutique humaine
DE19747063A1 (de)	1997-10-24	1999-04-29	Basf Ag	3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
US6267784B1 (en)	1998-05-01	2001-07-31	Benz Research And Development Corporation	Intraocular lens and haptics made of a copolymer
US6844344B2 (en)	1999-12-20	2005-01-18	Eli Lilly And Company	Benzofuran derivatives
DE10041574A1 (de)	2000-08-24	2002-03-07	Merck Patent Gmbh	Chromenonderivate
WO2002048105A2 (en)	2000-11-16	2002-06-20	Wyeth	Aryloxy piperidinyl derivatives for the treatment of depression
GB0101577D0 (en)	2001-01-22	2001-03-07	Smithkline Beecham Plc	Compounds
AR032641A1 (es)	2001-01-29	2003-11-19	Otsuka Pharma Co Ltd	Agonista de subtipo de receptor 5-ht 1a.
ATE312094T1 (de)	2001-06-29	2005-12-15	Lundbeck & Co As H	Neue heteroarylderivate, deren herstellung und verwendung
GB0227240D0 (en)	2002-11-21	2002-12-31	Glaxo Group Ltd	Compounds
TW200507841A (en)	2003-03-27	2005-03-01	Glaxo Group Ltd	Antibacterial agents
US7160888B2 (en) *	2003-08-22	2007-01-09	Warner Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

2004
- 2004-07-28 US US10/900,210 patent/US7160888B2/en not_active Expired - Fee Related
- 2004-08-13 GE GEAP20049246A patent/GEP20084447B/en unknown
- 2004-08-13 KR KR1020077009877A patent/KR100801794B1/ko not_active Expired - Fee Related
- 2004-08-13 CA CA2538915A patent/CA2538915C/en not_active Expired - Fee Related
- 2004-08-13 MX MXPA06002070A patent/MXPA06002070A/es active IP Right Grant
- 2004-08-13 AP AP2006003525A patent/AP2006003525A0/xx unknown
- 2004-08-13 OA OA1200600052A patent/OA13238A/en unknown
- 2004-08-13 BR BRPI0413860-0A patent/BRPI0413860A/pt not_active IP Right Cessation
- 2004-08-13 WO PCT/IB2004/002665 patent/WO2005019215A1/en not_active Ceased
- 2004-08-13 CN CNB2004800241500A patent/CN100422181C/zh not_active Expired - Fee Related
- 2004-08-13 NZ NZ545078A patent/NZ545078A/en unknown
- 2004-08-13 RS RSP-2006/0129A patent/RS20060129A/sr unknown
- 2004-08-13 AU AU2004266191A patent/AU2004266191B2/en not_active Ceased
- 2004-08-13 EA EA200600294A patent/EA009645B1/ru not_active IP Right Cessation
- 2004-08-13 UA UAA200601890A patent/UA82541C2/uk unknown
- 2004-08-13 ME MEP-453/08A patent/MEP45308A/xx unknown
- 2004-08-13 JP JP2006523707A patent/JP4034811B2/ja not_active Expired - Fee Related
- 2004-08-13 EP EP04744287A patent/EP1660497A1/en not_active Withdrawn
- 2004-08-13 KR KR1020067003621A patent/KR100765668B1/ko not_active Expired - Fee Related
- 2004-08-18 PE PE2004000796A patent/PE20051039A1/es not_active Application Discontinuation
- 2004-08-20 NL NL1026892A patent/NL1026892C2/nl not_active IP Right Cessation
- 2004-08-20 AR ARP040103006A patent/AR045386A1/es not_active Application Discontinuation
- 2004-08-20 HN HN2004000319A patent/HN2004000319A/es unknown
- 2004-08-20 MY MYPI20043415A patent/MY140693A/en unknown
- 2004-08-20 PA PA20048609701A patent/PA8609701A1/es unknown
- 2004-08-20 TW TW093125196A patent/TWI298327B/zh active
2005
- 2005-01-13 GT GT200500007A patent/GT200500007A/es unknown
2006
- 2006-01-20 NO NO20060324A patent/NO20060324L/no not_active Application Discontinuation
- 2006-01-26 IS IS8267A patent/IS8267A/is unknown
- 2006-01-30 IL IL173439A patent/IL173439A0/en unknown
- 2006-02-10 CU CU20060028A patent/CU23464B7/es not_active IP Right Cessation
- 2006-02-21 ZA ZA200601526A patent/ZA200601526B/en unknown
- 2006-02-22 CR CR8254A patent/CR8254A/es unknown
- 2006-02-22 TN TNP2006000063A patent/TNSN06063A1/en unknown
- 2006-02-22 EC EC2006006391A patent/ECSP066391A/es unknown
- 2006-02-22 MA MA28828A patent/MA28003A1/fr unknown
- 2006-08-24 US US11/466,828 patent/US20060287310A1/en not_active Abandoned
- 2006-08-24 US US11/466,822 patent/US20060287309A1/en not_active Abandoned
2008
- 2008-03-27 CR CR9834A patent/CR9834A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
GT200500007A (es)	2005-10-24
IS8267A (is)	2006-01-26
OA13238A (en)	2006-12-13
NL1026892A1 (nl)	2005-02-28
ECSP066391A (es)	2006-08-30
BRPI0413860A (pt)	2006-10-24
WO2005019215A1 (en)	2005-03-03
KR100765668B1 (ko)	2007-10-10
HN2004000319A (es)	2010-06-09
MY140693A (en)	2010-01-15
PA8609701A1 (es)	2005-05-24
ZA200601526B (en)	2007-04-25
US7160888B2 (en)	2007-01-09
AP2006003525A0 (en)	2006-02-28
JP4034811B2 (ja)	2008-01-16
MA28003A1 (fr)	2006-07-03
TNSN06063A1 (en)	2007-10-03
RS20060129A (sr)	2008-06-05
CN100422181C (zh)	2008-10-01
KR100801794B1 (ko)	2008-02-05
US20060287310A1 (en)	2006-12-21
CA2538915C (en)	2010-06-15
CR9834A (es)	2008-04-21
EP1660497A1 (en)	2006-05-31
MEP45308A (en)	2011-02-10
HK1091815A1 (zh)	2007-01-26
TW200524938A (en)	2005-08-01
CN1839134A (zh)	2006-09-27
NZ545078A (en)	2009-09-25
NL1026892C2 (nl)	2005-11-21
AR045386A1 (es)	2005-10-26
UA82541C2 (uk)	2008-04-25
CU23464B7 (es)	2009-12-17
US20060287309A1 (en)	2006-12-21
CR8254A (es)	2006-10-17
MXPA06002070A (es)	2006-05-19
EA009645B1 (ru)	2008-02-28
JP2007503386A (ja)	2007-02-22
AU2004266191A1 (en)	2005-03-03
KR20070053364A (ko)	2007-05-23
GEP20084447B (en)	2008-08-10
EA200600294A1 (ru)	2006-08-25
TWI298327B (en)	2008-07-01
PE20051039A1 (es)	2005-12-12
KR20060071404A (ko)	2006-06-26
US20050043309A1 (en)	2005-02-24
AU2004266191B2 (en)	2009-11-26
IL173439A0 (en)	2006-06-11
CA2538915A1 (en)	2005-03-03

Publication	Publication Date	Title
NO20060324L (no)	2006-05-18	[1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20051826L (no)	2005-04-15	Heterosyklisk substituerte piperaziner for behandling av schizofreni
NO20065456L (no)	2007-01-04	Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet
NO20074592L (no)	2007-10-19	Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20074258L (no)	2007-11-27	Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20053645L (no)	2002-10-22	(4R)- og (4S)-diastereoisomerer av (2S)-2-[ 2-oksy-4-propylpyrrolidinyl]butanamid og farmasoytisk preparat inneholdende disse
NO331068B1 (no)	2011-09-26	Benzazepinderivater for behandling av nevrologiske forstyrrelser.
NO20081729L (no)	2008-05-16	Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20063787L (no)	2006-09-19	Terapeutiske preparater
BG108650A (en)	2005-04-30	Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
NO20092342L (no)	2009-07-02	Azaspiroderivativater
NO20055688L (no)	2006-01-09	Organiske forbindelser
NO20083919L (no)	2008-12-19	Pyridin- og pyrimidinderivater som mGluR2-antagonister
MXPA03011484A (es)	2004-03-18	Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
NO20092412L (no)	2009-08-19	Hydantoinderivater anvendes som MMP-inhibitorer
NO20061363L (no)	2006-04-24	Pyrazolo- og imidazo- pyrimidinderivater
NO20076197L (no)	2008-02-29	Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
MX2007000505A (es)	2007-06-25	Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
TW200503710A (en)	2005-02-01	Novel compounds
GB0313612D0 (en)	2003-07-16	Organic compounds
ATE372995T1 (de)	2007-09-15	Benzo(b)(1,4)dioxepinderivate
NO20075477L (no)	2007-12-13	Tetrahydro-pyridoazepin-8-one og beslektede forbindelser for behandling av schizofreni
MY128241A (en)	2007-01-31	Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
NO20062256L (no)	2006-06-06	Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
EP1725536B8 (en)	2009-04-22	Imidazoline derivatives having cb1-antagonistic activity

Legal Events

Date	Code	Title	Description
2012-03-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application